Global market data

Cryptocurrencies: 6,286
Markets: 574
Marketcap: $ 1.48 T
24h Vol: $ 229.82 B
BTC Dominance: 59.66%

BioMarin Pharmaceutical Inc. (BMRN) Stock Price, Quote & News

B
BioMarin Pharmaceutical Inc.
BMRN
$77.43
5.3%

Notice: Undefined index: symbol in /home/u908330461/domains/liquidary.com/public_html/wp-content/plugins/massive-stock-widgets/includes/api.php on line 362

Notice: Undefined index: symbol in /home/u908330461/domains/liquidary.com/public_html/wp-content/plugins/massive-stock-widgets/includes/api.php on line 362

Notice: Undefined index: symbol in /home/u908330461/domains/liquidary.com/public_html/wp-content/plugins/massive-stock-widgets/includes/api.php on line 365

Notice: Undefined index: company_name in /home/u908330461/domains/liquidary.com/public_html/wp-content/plugins/massive-stock-widgets/includes/api.php on line 365

Stock Screener

BioMarin Pharmaceutical Inc.

EQUITY

type

Healthcare

sector

3.00K

#employees

770 Lindaro Street
94901, San Rafael, CA

United States

address

BioMarin Pharmaceutical Inc.
Status: Active
Sector: Healthcare
Industry: Biotechnology
Employees: 3001
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
Phone415 506 6700
Websitehttp://www.biomarin.com
y8
ad

BioMarin Pharmaceutical Inc.​ |

Stock Market Data
BioMarin Pharmaceutical Inc.​

Market Data

Open

$80.31 

Close vs last close

$81.76 vs $81.76

High

$80.46

Low

$75.30

Price

$77.43

Market Cap

$14.06B

24h volume

3.03M

# shares

181.53M

24h Change

$4.33

24h Change (%)

-5.30

52W high

$131.95

52w LOW

$68.25

Dividend yield

Dividend rate

eps

4.53

Subscribe To Our Newsletter 📬

Subscribe To Our Newsletter 📬

 

Join the Liquidary Newsletter to stay up to date on recent movements in markets, insights and educational content. We will occasionally reach out to you with original content and updates on Liquidary.

 

You have Successfully Subscribed!